This is a randomized, open-label, multicenter, phase III, superiority study of the effect of adding SBRT treatment to standard therapy on overall survival in patients with rare oligometastatic cancers.
Aim of the study
In our research project, we want to find out whether stereotactic radiotherapy (SBRT) for the treatment of oligometastases helps to better control your cancer and prevent it from spreading further.
Who can take part?
Patients with rare oligometastatic cancers
Procedure
If you are suitable and agree to participate, you will be randomly divided into 2 groups (1:1). If you are assigned to arm 1 (standard arm), you will receive the standard treatment, which may include palliative radiotherapy. If you are assigned to arm 2 (investigational arm), you will receive standard treatment, plus your oligoma tetastatic lesions will be treated with SBRT.
Compensation
None
Original study name
Stereotactic radiotherapy in addition to standard treatment in patients with rare oligometastatic cancers (OligoRARE): a randomized open-label phase III trial
BASEC number
2021-00693
Financial support from
European Organization forResearch and Treatment of Cancer (EORTC)